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CANCER MECHANISMS
Why Cancer and Inflammation?
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Central to the development of cancer are genetic changes that endow these “cancer cells”
with many of the hallmarks of cancer, such as self-sufficient growth and resistance to anti-
growth and pro-death signals. However, while the genetic changes that occur within cancer
cells themselves, such as activated oncogenes or dysfunctional tumor suppressors, are re-
sponsible for many aspects of cancer development, they are not sufficient. Tumor promotion
and progression are dependent on ancillary processes provided by cells of the tumor envi-
ronment but that are not necessarily cancerous themselves. Inflammation has long been as-
sociated with the development of cancer. This review will discuss the reflexive relationship
between cancer and inflammation with particular focus on how considering the role of inflam-
mation in physiologic processes such as the maintenance of tissue homeostasis and repair
may provide a logical framework for understanding the connection between the inflammatory
response and cancer.
INTRODUCTION
Basics of cancer development
Cancer results from the outgrowth of a
clonal population of cells from tissue. The
development of cancer, referred to as car-
cinogenesis, can be modeled and character-
ized in a number of ways. One way to
describe this process is to illustrate the es-
sential features of both cancer cells and tu-
mors: the “hallmarks” of cancer [1]. Cancer
development requires the acquisition of six
fundamental properties: self-sufficient pro-
liferation, insensitivity to anti-proliferative
signals, evasion of apoptosis, unlimited
replicativepotential,themaintenanceofvas-
cularization, and, for malignancy, tissue in-
vasion and metastasis [1]. Cancer can also
beconsideredwithregardtoastep-wisede-
velopment functionally grouped into three
phases: initiation, promotion, and progres-
sion [2]. Initiation is characterized by ge-
nomicchangeswithinthe“cancercell,”such
aspointmutations,genedeletionandampli-
fication, and chromosomal rearrangements
leading to irreversible cellular changes.
Tumordevelopmentispromotedbythesur-
vival and clonal expansion of these “initi-
ated” cells. Progression encompasses a
substantial growth in tumor size and either
growth-relatedormutuallyexclusivemetas-
tasis.
Essential to the development of cancer
is the accumulation of genetic lesions in
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initiationbutmayalsobeinvolvedinthepro-
motionorprogressionoftumordevelopment
[2]. These genome-level events include the
activation of cellular proto-oncogenes or in-
activation of tumor suppressor genes, which
act in a “cancer-cell intrinsic” manner be-
stowing these cells with certain properties.
However, while these cell autonomous prop-
erties are necessary for tumorigenesis, they
are not sufficient. Research over the last two
decades has solidified the concept that tumor
development and malignancy is the result of
processes involving both the cancer cells
themselves and non-cancer cells, many of
which compose the heterocellular tumor. A
clear example of this is illustrated by the re-
quirement of neo-angiogenesis for tumor
growthandthusthecontributionofthevascu-
lar endothelial cells [3].
Cancer and inflammation
An association between the develop-
ment of cancer and inflammation has long-
been appreciated [4,5]. The inflammatory
response orchestrates host defenses to mi-
crobial infection and mediates tissue repair
and regeneration, which may occur due to
infectious or non-infectious tissue damage.
Epidemiological evidence points to a con-
nection between inflammation and a predis-
position for the development of cancer, i.e.
long-term inflammation leads to the devel-
opment of dysplasia. Epidemiologic studies
estimate that nearly 15 percent of the world-
wide cancer incidence is associated with mi-
crobial infection [6]. Chronic infection in
immunocompetent hosts such as human pa-
pilloma virus or hepatitis B and C virus in-
fection leads to cervical and hepatocellular
carcinoma, respectively. In other cases, mi-
crobes may cause cancer due to opportunis-
tic infection such as in Kaposi’s sarcoma (a
result of human herpes virus (HHV)-8 infec-
tion) or inappropriate immune responses to
microbes in certain individuals, which may
occur in gastric cancer secondary to Heli-
cobacter pylori colonization or colon cancer
because of long-standing inflammatory
bowel disease precipitated by the intestinal
microflora [4,5]. In many other cases, condi-
tions associated with chronic irritation and
subsequent inflammation predispose to can-
cer, such as the long-term exposure to ciga-
rette smoke, asbestos, and silica [4,5].
Observing signs of inflammation, such
as leukocyte infiltration, at tumors infected
with microbes or sites of chronic irritation is
expected. However, as first observed byVir-
chowinthemiddleofthe19thcentury,many
tumors for which infection or irritation are
notnecessarilyapredisposingfactor,suchas
mammory adenocarcinoma, show a “lym-
phoreticular infiltrate.” Many tumors of this
type contain activated fibroblasts and
macrophages, in addition to a gene expres-
sion profile with an inflammatory signature.
Quantitative aspects of wound repair or in-
flammatory gene expression often correlate
negatively with cancer stage and prognosis
[7-9].Furtherevidencefortheroleofinflam-
mation has come from the use of non-
steroidalanti-inflammatorydrugs(NSAIDs)†
in the prevention of spontaneous tumor for-
mation in people with familial adenomatous
polyposis (FAP) [10]. Thus, cancer and in-
flammation are related by epidemiology,
histopathology, inflammatory profiles, and
the efficacy of anti-inflammatory drugs in
prophylaxis. These observations have pro-
vided impetus for investigation and hypoth-
esis on the mechanisms and semantics of the
relationship between cancer and inflamma-
tion.
There is evidence to suggest the inflam-
matory and immune systems may inhibit the
development of cancer. This may occur by
two cancer-associated recognition events. In
tumor immunosurveillance, the host may
have a dedicated mechanism to perceive and
eliminate transformed cells. Adaptive im-
mune recognition of tumor-associated and
specific antigens also may be an important
meansbywhichtheimmunesystemcontrols
the development of cancer [11]. Such topics
will not be covered here. However, it seems
the net effect of the inflammatory system is
to positively affect tumor development. The
relationship between cancer and inflamma-
tion is not simple and cannot be reduced to
one grand theory. Previous reviews have fo-
cused on various aspects of the relationship
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the role of various inflammatory cells
[4,12,13], mediators [4,14-16], or signaling
pathways [17] in cancer. The focus of this
essay will be to discuss the relationship be-
tweencancerandinflammationalongtheor-
ganizing principle that the inflammatory
response maintains physiological processes
such as tissue homeostasis and repair after
injuryandthatinthisrole,inflammationmay
be an ancillary, or perhaps inseparable, as-
pect of tumor development.
INFLAMMATION CAN
CAUSE CANCER
As stated, long-standing inflammation
secondary to chronic infection or irritation
predisposestocancer.Howmightsuchcondi-
tions lead to the emergence of initiated cells?
In the case of some types of viral infection, it
is clear that virally encoded genes can con-
tributetocellulartransformation. Anexample
of this are the transformative abilities of high
risk HPV mediated by the oncoproteins E6
and E7 [18]. However, many microbes asso-
ciatedwithcancercannottransformcells.For
example, while certain strains of H. pylori
contain factors that affect host cell signaling,
they are not classical oncogenes [19].
The chronic inflammatory states asso-
ciated with infection and irritation may lead
to environments that foster genomic lesions
and tumor initiation. One effector mecha-
nism by which the host fights microbial in-
fection is the production of free radicals
such as reactive oxygen intermediated
(ROI), hydroxyl radical (OH•) and superox-
ide (O2-•) and reactive nitrogen intermedi-
ates (RNI), nitric oxide (NO•) and
peroxynitrite (ONOO-). Primarily thought
to be anti-microbial, these molecules form
due to the activities of host enzymes such as
myeloperoxidase, NADPH oxidase, and ni-
tric oxide, which are regulated by inflamma-
tory signaling pathways. Importantly, ROI
and RNI lead to oxidative damage and nitra-
tion of DNA bases which increases the risk
of DNAmutations [20].
Cells have intrinsic mechanisms by
which to prevent unregulated proliferation
or the accumulation of DNA mutations.
These include tumor suppressor pathways
that mediate DNA repair, cell cycle arrest,
apoptosis and senescence. In the face of
DNAdamage or oncogenic activation, cells
will either repair their DNAand prevent mu-
tations or initiated cells will undergo cell
death.
In the face of massive cell death as oc-
curs in infection or non-infectious tissue in-
jury, lost cells must be repopulated by the
expansion of other cells, often undifferenti-
ated precursor cells such as tissue stem cells.
There are two requisites for this: Some cells
must survive the injury, and cells must ex-
pand to maintain cell numbers for a proper
functioning tissue. Many inflammatory
pathways function to mediate these two pre-
requisites of tissue repair [21,22]. In an ex-
tension of its physiologic role in mediating
tissue repair or as a strategy in host defense
to infection, the inflammatory response may
play a role in providing survival and prolif-
erative signals to initiated cells, thereby
leading to tumor promotion.
Direct evidence for a link between tu-
morigenesis and either host defense and tis-
sue repair has come from a number of
observations. Many molecules and path-
ways double-up, playing roles in homeosta-
sis, tissue repair, and tumorigenesis. The
Wnt/ʲ-catenin pathway plays a critical role
in both the maintenance of the steady-state
proliferative compartment and tumorigene-
sis of tissues [23]. Molecules such as COX-
1 and -2, involved in the synthesis of
prostaglandins that mediate the tissue repair
process in the alimentary tract [24-26], play
critical roles in tumor development at these
sites [27,28]. For the most part, these obser-
vations are only associations, based on an
entity’s (enzyme or transcription factor) in-
volvement in tissue repair and tumorigene-
sis. However, key supportive evidence to
connect these processes has come from stud-
ies showing that dedicated tissue injury and
wounding supports tumor growth and neo-
plastic progression. Injection of Rous sar-
coma virus (RSV) into chickens leads to the
growth of a sarcoma at the site of injection.
Work over the years by the Bissell labora-
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other sites of the chicken if that site is
wounded [29]. The promotion of these
wound-related tumors can be inhibited by
glucocorticoids and may be mediated by the
actions of transforming growth factor-ʲ
(TGF-ʲ) and fibroblast growth factors
(FGFs) [30-32]. In a B16 melanoma adop-
tive transfer study, tumor growth is en-
hanced in wounded limbs by the induction
of paracrine factors such as TGF-ʲ and
bFGF in wound fluid [33].
Recent studies investigating the role of
NF-ʺB (a family of transcription factors
central to the induction of inflammation) in
tumorigenesis has provided some more de-
tailed insights into the role of inflammation
in tumor promotion. Greten et al. used a
model of colitis associated cancer (CAC) in-
duced by the intraperitoneal injection of the
carcinogen azoxymethane (AOM), followed
by multiple rounds of inflammation and
leukocyte infiltration caused by administra-
tion of the colonic epithelial cell toxin, dex-
tran sulfate sodium (DSS) [34]. In this
system, it is clear that chronic inflammation
augments tumorigenesis, as when one dose
of AOM is given without DSS cycling, no
tumors arise. How then does the inflamma-
tory response affect tumorigenesis in this
model? Inactivation of the classical NF-ʺB
pathway in colonic epithelial cells by con-
ditional deletion of the IʺB kinase ʲ (IKKʲ)
protein resulted in a substantial decrease in
the frequency of visible tumors [34]. Impor-
tantly, NF-ʺB signaling in epithelial cells
was required for inhibition of apoptosis
shortly after administration of one round of
AOM and DSS, perhaps by the induction of
anti-apoptotic factors such as Bcl-XL. Thus
upon intestinal epithelial injury and the ad-
dition of a mutagen, NF-ʺB provides a sur-
vival signal to initiated cells. Importantly,
IKKʲ in the colonic epithelium is responsi-
ble for mediating epithelial cell survival in
protection from both infectious and non-in-
fectious injury [22,35,36] and host defense
pathways in intestinal epithelium [37]. A
similar role for NF-ʺB in survival of initi-
ated cells was demonstrated in a chronic in-
flammation model of hepatocellular
carcinoma, which develops spontaneously
in Mdr2-deficient mice [38]. In this model,
when NF-ʺB activation was inhibited by use
of a super-repressor of degradation of IʺB
selectively expressed in hepatic epithelial
cells, there was an increased number of
apoptotic hepatocytes, a finding which cor-
related with a decreased frequency of tumors
compared to Mdr2-/- mice with degradable
IʺB [38].
Tumor promotion requires not only the
survival of initiated cells, but also their ex-
pansion. Many inflammatory mediators
such as cytokines, chemokines, and
eicanosoids are capable of stimulating the
proliferation of both untransformed and
tumor cell proliferation [4]. Mice deficient
inTNF have fewer skin tumors upon admin-
istration of the phorbol ester TPA and the
mutagen DMBA [39]. Investigation into
howTNF regulates tumor progression in this
model suggested that this inflammatory me-
diator acts as a tumor promotor, since soon
after application of TPA/DMBA, the char-
acteristic hyperproliferation of keratinocytes
was shown to be dependent on TNF [39].
What induces this production of inflamma-
tory mediators, such as TNF, which leads to
expansion of tumor initiated cells? NF-ʺB
activation in myeloid cells recently was
shown to play a critical role in the produc-
tion of inflammatory mediator in both the
AOM/DSS model of CAC [34] and muta-
gen-induced hepatocellular carcinoma upon
administration of diethylnitroseamine
(DEN) [40]. In both of these models, when
myeloid cells were defective in activating
NF-ʺB via the classical pathway, there was
impaired production of inflammatory medi-
ators, proliferation of dysplastic epithelium,
and a decrease in both the frequency and
size of tumors compared to WT mice [40].
Many of these factors, such as IL-6, are re-
quired for hepatic regeneration after injury
[41].An important finding of the DEN study
was that when NF-ʺB was impaired in he-
patocytes, there was increased epithelial cell
death, yet a increased tumor burden [40].
This finding suggests that myeloid cells may
lead to proliferation of initiated cells by de-
tecting epithelial cell death [42].Thus, in the
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and massive cellular death, activation of an
inflammation dependent tissue repair/com-




Pre-malignant tumors are “wound-like”
[43]. Such tumors are similar to healing or
desmoplastictissueinmanyways,suchasthe
presenceofactivatedplatelets[44,45].Asde-
scribed by Coussens and Hanahan, tumor
growth may be “biphasic” [43]. In the first
phase,thebodytreatsearlytumorsaswounds.
This phase is characterized by tumor growth
mediated by the actions of the stroma “indi-
rect control” as occurs in physiologic tissue
repair.Forexample,inmurinemodelsofskin
and pancreatic carcinogenesis, bone-marrow
derivedcells,includingmastcells,arerespon-
sible for providing matrix metalloproteases
which convert VEGF into a biological active
form to stimulate the pro-tumorigenic angio-
genic switch [43,46,47]. However, during
later tumor growth, it appears pro-inflamma-
toryfactors,suchasMMPs,comeunderdirect
controlbythetumorsthemselves[43].Asim-
ilar transition in the regulation of inflamma-
tionbyearlyvs.latetumorsmaybeathandin
spontaneous intestinal tumorigenesis in both
mice and humans. COX-2 is expressed by
stromal cells in early tumors [48,49], perhaps
aspartofaresponsetoearlytumorassociated
wounding; in larger tumors, COX-2 is ex-
pressed by the dysplastic epithelium itself
[50].Oneintriguinghypothesisastowhythis
phenomenon occurs is that there are intact
regulatory mechanisms present in tumor as-
sociated stromal cells, limiting their expres-
sion of tissue repair factors. This may lead to
theselectiveemergenceoftumorcellsthatau-
tonomously can maintain these ancillary
processes and are not dependent on the
“wound-like stroma.” Eventually, however,
the tumor associated stroma may undergo se-
lective pressure, as there have been recent re-
ports of genetic changes in tumor associated
stroma[51]andevenlossofp53intumor-as-
sociated fibroblasts [52].
In addition to playing a critical role in
tumor growth, such as by mediating angio-
genesis, the inflammatory response may
have a role in other aspects of progression,
such as tissue invasion and metastasis. An-
giogenesis itself augments vascular invasion
of migrating cells. Matrix metalloproteases
and their inhibitors (TIMPs) are critical for
angiogenesis and also in remodeling of ex-
tracellular matrix [14]. Infiltrating leuko-
cytes may further aid tumor progression by
blazing a trail throughthe ECM, the counter-
current invasion theory [53].
PROSPECTUS
As delineated above, the cell death and
tissue injury that may occur right after initi-
ation may induce tissue repair and homeo-
static responses leading to tumor
progression. In addition, signals derived
from microbes also might activate innate mi-
crobial recognition pathways enhancing the
development of tumors. In this manner, the
inflammatory response plays a causative
role in early tumor development via regula-
tion of initiation and promotion.
Mutagens lead to DNA damage, and
DNA damage may activate NF-ʺB via cell
death or by DNA damage itself [54]. While
such cell death is likely to be below the
threshold required for compensatory prolif-
eration and tumor promotion, repeated ex-
posure to mutagens may cause enough cell
death to warrant the survival of some initi-
ated cells and their expansion. Repeated ex-
posure of mice to mutagens alone (such as
AOM) can induce tumorigenesis. Given that
the life history of mammals is rife with both
temporary (infection or burns) and constant
environmental insults (ingested or airborne
irritants), exposure to mutagens is likely to
be coupled with some form of low level ir-
ritation or injurous agent. Thus, mutagens
and irritants/infection may be at work in car-
cinogenesis in more cases and ways than
previously estimated.
As cancers grow, tissues change in
many ways. Much of these changes may re-
semble tissue injury and induce homeostatic
mechanisms to maintain tissue function. For
127 Rakoff-Nahoum: Why cancer and inflammation?example, the ischemia at the core of a solid
tumor may initiate a physiologic response to
hypoxia, such as activation of the HIF1
pathway and subsequent angiogenesis.
Growing tumors also might degrade epithe-
lial barriers, the cellular architecture of tis-
sues, or disrupt the extracellular matrix.All
of these processes are likely to stimulate
homeostatic processes of tissue repair, in-
cluding the recruitment of inflammatory
leukocytes. These responses lead to tumor
growth itself, thus promoting a positive
feedback loop [44].
The next step in understanding the rela-
tionshipbetweenhomeostaticprocesses,such
as compensatory proliferation, tissue repair,
andhostdefense,andtumorigenesiswillbeto
determine whether pattern recognition of dis-
turbances in homeostasis are involved in tu-
morigenesis.Are these pathways involved in
intitiating tumor associated inflammation?





of virus and bacteria [60]. In addition, it has
been purported that certain receptors may be
involved in sensation of tissue injury and cell
death,suchasthosethatrecognizeextracellu-
lar matrix fragments (such as hyaluronan or
fibronectin)ornecroticdebris(includingS100
and heat shock proteins and HMGB1). Any
rolefortheserecognitionpathwaysintumori-
genesis is ripe for investigation.
An open question is what role innate
pattern recognition pathways have in car-
cinogenesis secondary to microbial colo-
nization, such as in H. pylori-induced gastric
carcinoma. It will be important to determine
the relative contributions of microbe-derived
factors critical for microbial colonization
and survival in the host (such as “virulence”
or “adaptation” factors) and host-determined
responses (such as inflammation) in tumor
development as well as to determine synergy
between these factors. Such investigations
may identify important information regard-
ing why certain forms of chronic inflamma-
tion do or do not predispose to tumor
development.
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